GCTK (GlucoTrack) ROCE % : -227.16% (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GlucoTrack's annualized ROCE % for the quarter that ended in Mar. 2025 was -227.16%.

GlucoTrack ROCE % Historical Data

The historical data trend for GlucoTrack's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack ROCE % Chart

GlucoTrack Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-77.48

-54.37

-130.22

-294.60

-545.81

GlucoTrack Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-587.70	-	-	-10,344.95	-227.16

GlucoTrack ROCE % Calculation

GlucoTrack's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-21.969	/	( ( (4.905 - 1.512)	+	(5.932 - 1.275) )	/ 2 )
	=	-21.969	/	( (3.393	+	4.657)	/ 2 )
	=	-21.969	/	4.025
	=	-545.81 %

GlucoTrack's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-13.992	/	( ( (5.932 - 1.275)	+	(9.612 - 1.95) )	/ 2 )
	=	-13.992	/	( ( 4.657	+	7.662 )	/ 2 )
	=	-13.992	/	6.1595
	=	-227.16 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

GlucoTrack (NAS:GCTK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GlucoTrack ROCE % Related Terms

Thank you for viewing the detailed overview of GlucoTrack's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GlucoTrack Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070

Website

https://www.glucotrack.com

GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.

Executives

Drew Sycoff	director	C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
James S Cardwell	officer: Chief Financial Officer	CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter	director	301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig	director	301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps	director	C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
David Podwalski	officer: Chief Commercial Officer	19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck	director	19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham	director, officer: Chief Executive Officer	19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun	officer: Chief Financial Officer	39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff	director	1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz	director	19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Leslie Seff	director	PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Angela Strand Boydston	director	C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Eran Hertz	officer: Chief Financial Officer	C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich	director	C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100